Pablo Sarobe

Dr. Pablo Sarobe

Department of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, 31009 Pamplona, Spain
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
BSBruno Sangro
Bruno Sangro
PSPablo Sarobe
Pablo Sarobe
SHSandra Hervás-Stubbs
Sandra Hervás-Stubbs
IMIGNACIO MELERO
IGNACIO MELERO

1 July 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
BSBruno Sangro
Bruno Sangro
CGCarlos Gomez-Martin
Carlos Gomez-Martin
MMManuel de la Mata
Manuel de la Mata
MIMercedes Iñarrairaegui
Mercedes Iñarrairaegui
EGElena Garralda
Elena Garralda
JPJesús Prieto
Jesús Prieto

1 August 2017 in Cell Reports
Verified
Journal Article
Open access
MGMaria Gato-Cañas
Maria Gato-Cañas
MZMiren Zuazo
Miren Zuazo
Hugo Arasanz EstebanHugo Arasanz Esteban
Hugo Arasanz Esteban
MIMaria Ibañez-Vea
Maria Ibañez-Vea
LLLaura Lorenzo
Laura Lorenzo
DEDavid Escors
David Escors
PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer cells from interferon (IFN) cytotoxicity and accelerates tumor progression. PDL1 inhibited IFN signal transduction through a conserved class of sequence motifs that mediate crosstalk with IFN signaling. Abrogation of PDL1 expression or antibody-mediated PDL1 blockade strongly sensitized cancer cells to IFN cytotoxicity through a STAT3/caspase-7-dependent pathway. Moreover, somatic mutations found in human carcinomas within these PDL1 sequence motifs disrupted motif regulation, resulting in PDL1 molecules with enhanced protective activities from type I and type II IFN cytotoxicity. Overall, our results reveal a mode of action of PDL1 in cancer cells as a first line of defense against IFN cytotoxicity.

1 December 2003 in The Journal of Immunology
Verified
Journal Article
Closed access
NCNoelia Casares
Noelia Casares
LALaura Arribillaga
Laura Arribillaga
PSPablo Sarobe
Pablo Sarobe
JDJavier Dotor
Javier Dotor
ACAscensión Lopez-Diaz de Cerio
Ascensión Lopez-Diaz de Cerio
JLJuan José Lasarte
Juan José Lasarte
CD25+ regulatory T (T reg) cells suppress the activation/proliferation of other CD4+ or CD8+ T cells in vitro. Also, down-regulation of CD25+ T reg cells enhance antitumor immune responses. In this study, we show that depletion of CD25+ T reg cells allows the host to induce both CD4+ and CD8+ antitumoral responses following tumor challenge. Simultaneous depletion of CD25+ and CD8+ cells, as well as adoptive transfer experiments, revealed that tumor-specific CD4+ T cells, which emerged in the absence of CD25+ T reg cells, were able to reject CT26 colon cancer cells, a MHC class II-negative tumor. The antitumoral effect mediated by CD4+ T cells was dependent on IFN-γ production, which exerted a potent antiangiogenic activity. The capacity of the host to mount this antitumor response is lost once the number of CD25+ T reg cells is restored over time. However, CD25+ T reg cell depletion before immunization with AH1 (a cytotoxic T cell determinant from CT26 tumor cells) permits the induction of a long-lasting antitumoral immune response, not observed if immunization is conducted in the presence of regulatory cells. A study of the effect of different levels of depletion of CD25+ T reg cells before immunization with the peptide AH1 alone, or in combination with a Th determinant, unraveled that Th cells play an important role in overcoming the suppressive effect of CD25+ T reg on the induction of long-lasting cellular immune responses.

28 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LHLaura Hato
Laura Hato
AAAngel Vizcay Atienza
Angel Vizcay Atienza
IEIñaki Eguren
Iñaki Eguren
JGJose Luis Perez Gracia
Jose Luis Perez Gracia
Javier Rodríguez RodríguezJavier Rodríguez Rodríguez
Javier Rodríguez Rodríguez
MSMarta Santisteban
Marta Santisteban
Cancer immunotherapy modulates the immune system, overcomes immune escape and stimulates immune defenses against tumors. Dendritic cells (DCs) are professional promoters of immune responses against tumor antigens with the outstanding ability to coordinate the innate and adaptive immune systems. Evidence suggests that there is a decrease in both the number and function of DCs in cancer patients. Therefore, they represent a strong scaffold for therapeutic interventions. DC vaccination (DCV) is safe, and the antitumoral responses induced are well established in solid tumors. Although the addition of checkpoint inhibitors (CPIs) to chemotherapy has provided new options in the treatment of cancer, they have shown no clinical benefit in immune desert tumors or in those tumors with dysfunctional or exhausted T-cells. In this way, DC-based therapy has demonstrated the ability to modify the tumor microenvironment for immune enriched tumors and to potentiate systemic host immune responses as an active approach to treating cancer patients. Application of DCV in cancer seeks to obtain long-term antitumor responses through an improved T-cell priming by enhancing previous or generating de novo immune responses. To date, DCV has induced immune responses in the peripheral blood of patients without a significant clinical impact on outcome. Thus, improvements in vaccines formulations, selection of patients based on biomarkers and combinations with other antitumoral therapies are needed to enhance patient survival. In this work, we review the role of DCV in different solid tumors with their strengths and weaknesses, and we finally mention new trends to improve the efficacy of this immune strategy.

1 April 2007 in Journal of Virology
Verified
Journal Article
Closed access
ELEsther Larrea
Esther Larrea
JRJosé-Ignacio Riezu-Boj
José-Ignacio Riezu-Boj
LGLucía Gil-Guerrero
Lucía Gil-Guerrero
NCNoelia Casares
Noelia Casares
RARafael Aldabe
Rafael Aldabe
JPJesús Prieto
Jesús Prieto
Indoleamine 2,3-dioxygenase (IDO) is induced by proinflammatory cytokines and by CTLA-4-expressing T cells and constitutes an important mediator of peripheral immune tolerance. In chronic hepatitis C, we found upregulation of IDO expression in the liver and an increased serum kynurenine/tryptophan ratio (a reflection of IDO activity). Huh7 cells supporting hepatitis C virus (HCV) replication expressed higher levels of IDO mRNA than noninfected cells when stimulated with gamma interferon or when cocultured with activated T cells. In infected chimpanzees, hepatic IDO expression decreased in animals that cured the infection, while it remained high in those that progressed to chronicity. For both patients and chimpanzees, hepatic expression of IDO and CTLA-4 correlated directly. Induction of IDO may dampen T-cell reactivity to viral antigens in chronic HCV infection.